RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret Valuation

Is RTALB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RTALB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RTALB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RTALB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RTALB?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for RTALB. This is calculated by dividing RTALB's market cap by their current preferred multiple.
What is RTALB's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

RTALB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	17.6x
Enterprise Value/EBITDA	-59.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does RTALB's PE Ratio compare to its peers?

The above table shows the PE ratio for RTALB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.5x
DTIL Precision BioSciences	5.3x	-41.3%	US$61.2m
6539 DV Biomed	26.6x	n/a	NT$1.4b
TRILC Turk Ilac Ve Serum Sanayi Anonim Sirketi	24.1x	n/a	₺3.1b
3164 GenMont Biotech Incorporation	26.2x	n/a	NT$1.9b
RTALB RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret	19.4x	n/a	₺1.7b

Price-To-Earnings vs Peers: RTALB is good value based on its Price-To-Earnings Ratio (19.4x) compared to the peer average (20.5x).

Price to Earnings Ratio vs Industry

How does RTALB's PE Ratio compare vs other companies in the Asian Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	48.2%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	48.2%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: RTALB is good value based on its Price-To-Earnings Ratio (19.4x) compared to the Asian Biotechs industry average (32.4x).

Price to Earnings Ratio vs Fair Ratio

What is RTALB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RTALB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	19.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RTALB's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.